Open Access Research article

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Arash Naeim1*, Henry J Henk2, Laura Becker2, Victoria Chia3, Sejal Badre4, Xiaoyan Li5 and Robert Deeter5

Author Affiliations

1 Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

2 OptumInsight, Health Economics and Outcomes, 12125 Technology Drive, Eden Prairie, MN, 55344, USA

3 Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA

4 Global Biostatistical Science, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA

5 Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA

For all author emails, please log on.

BMC Cancer 2013, 13:11  doi:10.1186/1471-2407-13-11

Published: 8 January 2013

Additional files

Additional file 1:

Appendix - Bacterial and Fungal Infections.

Format: DOCX Size: 34KB Download file

Open Data